Abstract

Targeted drug delivery using folate receptors is one of the most interesting chemotherapeutic research areas over the past few years. A novel folate targeted copolymer was synthesized using dextran stearate coupled to folic acid. FT-IR and NMR spectroscopy were used to confirm successful conjugation. Micelles prepared using this copolymer were characterized for their particle size, zeta potential, critical micelle concentration (CMC), drug loading capacity, and release efficiency. Cytotoxicity and cellular uptake of the micelles were estimated using CT-26 colorectal carcinoma cell line. FT-IR and NMR spectroscopy confirmed production of folate grafted dextran stearate copolymer. Low CMC value indicates that the copolymers are suitable for preparation of stable micelles useful in parenteral dosage forms. Particle size and zeta potential of the targeted nanoparticles were 105.5 ± 2.0 nm and −21.2 mV, respectively. IC50 of etoposide loaded in folate grafted dextran stearate enhanced about 20-fold compared to the pure drug (0.49 ± 0.11 μg/mL versus 9.41 ± 0.52 μg/mL). It seems that etoposide loaded in micelles of folate grafted dextran stearate copolymer is promising in reducing drug resistance of colorectal cancer by boosting etoposide cellular uptake.

Highlights

  • Colorectal cancer (CRC) contributes to over one million new cases annually and accounts for over one thousand deaths

  • Dextran molecular weight (Mw) of 6000 and 10000, stearoyl chloride, pyrene, and dialysis tube with cutoff 2 kDa were purchased from Sigma (USA); folic acid, dicyclohexylcarbodiimide (DCC), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethyl amino pyridine (DMAP), and 34,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) was from Merck Chemical Company (Germany)

  • Dextran stearate was synthesized by reaction of acyl chloride

Read more

Summary

Introduction

Colorectal cancer (CRC) contributes to over one million new cases annually and accounts for over one thousand deaths. CRC is the second most common cause of cancer mortality. CRC comprises 9% of the global cancer burden [1]. There are limited drug therapy choices for management of CRC. Many of these intervention therapies include exclusively 5-FU or 5-FU along with irinotecan, oxaliplatin, panitumumab, cetuximab, or bevacizumab. Despite using these combinations many CRC cases are drug resistant and the lack of novel remedies is sensible [2, 3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call